HopeStage
Back to all studies
CompletedNCT00274677

Lamotrigine or placebo for depression in bipolarity

About this title

Depression And Bipolar Disorder

Read the official source — NCT00274677
Placebo comparisonAges 18+United States
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Burbank and 18 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2003
Recruitment status
Completed
Enrollment listed in the registry
221
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT00274677
Official title
Show the full official title

A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients With Type II Bipolar Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Burbank · Loma Linda · San Diego

16 more locations
  • Marietta
  • Terre Haute
  • Shreveport
  • Saint Charles
  • Clementon
  • Princeton
  • New York
  • Pleasantville
  • Charlotte
  • Raleigh
  • Beachwood
  • Oklahoma City
  • Eugene
  • Columbia
  • Galveston
  • Houston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including Placebo and lamotrigine.

Who was this study for?

This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies